FDA Approves Promising Therapy for Advanced Prostate Cancer: Targets a Protein Called PSMA
This is an article from Memorial Sloan Kettering:
"Prostate cancer treatment took a major step forward today as the U.S. Food and Drug Administration approved a new therapy that zeros in on cancer cells to destroy them. The treatment, called 177Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface called PSMA (prostate-specific membrane antigen). The technology delivers radiation that damages DNA and destroys the cancer cell.
“This type of precision medicine is a game changer for people whose prostate cancer has spread despite receiving multiple treatments,” says Memorial Sloan Kettering Cancer Center medical oncologist Michael Morris. He helped design, execute, and analyze a clinical trial showing the effectiveness of 177Lu-PSMA-617. “FDA approval of this therapy will enable even more people who had essentially been given death sentences to survive and live well.”
Link to the article: https://www.mskcc.org/news/fda-approves-promising-therapy-advanced-prostate?utm_source=msknow-04-26-22&utm_medium=email&utm_content=generalcancer&utm_type=clinicalresearch